Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Beas-Lozano EL, Scagliarini S, Valdez-Sandoval PI, Esparza-Orozco MF, Bilen MA, Bamias A, Li H, Juan Fita MJ, Kopecky J, Manneh Kopp R, Ghosn M, Fay AP, Bhuva D, Kucharz J, Büttner T, Molina-Cerrillo J, Fiala O, Rizzo A, Maiorano BA, Soares A, Buti S, Marques Monteiro FS, Massari F, Santoni M, Bourlon MT

Open source

DOI: 10.3389/fimmu.2026.1805104
Published: 2026
Container: Frontiers in immunology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1805104,
  title = {Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).},
  author = {Beas-Lozano EL and Scagliarini S and Valdez-Sandoval PI and Esparza-Orozco MF and Bilen MA and Bamias A and Li H and Juan Fita MJ and Kopecky J and Manneh Kopp R and Ghosn M and Fay AP and Bhuva D and Kucharz J and Büttner T and Molina-Cerrillo J and Fiala O and Rizzo A and Maiorano BA and Soares A and Buti S and Marques Monteiro FS and Massari F and Santoni M and Bourlon MT},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1805104},
  url = {https://doi.org/10.3389/fimmu.2026.1805104}
}

RIS

TY  - JOUR
TI  - Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).
AU  - Beas-Lozano EL
AU  - Scagliarini S
AU  - Valdez-Sandoval PI
AU  - Esparza-Orozco MF
AU  - Bilen MA
AU  - Bamias A
AU  - Li H
AU  - Juan Fita MJ
AU  - Kopecky J
AU  - Manneh Kopp R
AU  - Ghosn M
AU  - Fay AP
AU  - Bhuva D
AU  - Kucharz J
AU  - Büttner T
AU  - Molina-Cerrillo J
AU  - Fiala O
AU  - Rizzo A
AU  - Maiorano BA
AU  - Soares A
AU  - Buti S
AU  - Marques Monteiro FS
AU  - Massari F
AU  - Santoni M
AU  - Bourlon MT
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1805104
UR  - https://doi.org/10.3389/fimmu.2026.1805104
ER  -

APA

EL, B., S, S., PI, V., MF, E., MA, B., A, B., H, L., MJ, J. F., J, K., R, M. K., M, G., AP, F., D, B., J, K., T, B., J, M., O, F., A, R., BA, M., A, S., S, B., FS, M. M., F, M., M, S., & MT, B. (2026). Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1805104

Source records

pubmed · retrieved 2026-09-26T05:44:43.062Z